83 results
DEFM14A
ORTX
Orchard Therapeutics plc
16 Nov 23
Proxy related to merger
4:45pm
and Cosmetic Act of 1938, as amended, other U.S. and foreign healthcare laws applicable to Orchard and its subsidiaries and the Controlled Substances Act … Capital”), by RA Capital Healthcare Fund, L.P. (the “Fund”), Peter Kolchinsky and Rajeev Shah on March 20, 2023, consists of (i) 16,720,000 ordinary shares
8-K
EX-99.1
ORTX
Orchard Therapeutics plc
13 Nov 23
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
7:05am
and Healthcare products Regulatory Agency (MHRA).
Commercial Updates and Newborn Screening Progress
In October, the Institute for Clinical and Economic Review
PREM14A
ORTX
Orchard Therapeutics plc
3 Nov 23
Preliminary proxy related to merger
5:11pm
with the U.S. Food, Drug and Cosmetic Act of 1938, as amended, other U.S. and foreign healthcare laws applicable to Orchard and its subsidiaries … on a Schedule 13G filed with the SEC by RA Capital Management L.P. (“RA Capital”), by RA Capital Healthcare Fund, L.P. (the “Fund”), Peter Kolchinsky
DEFA14A
ORTX
Orchard Therapeutics plc
17 Oct 23
Additional proxy soliciting materials
4:32pm
, talk and interact with the world around them. Libmeldy is approved by the European Commission (EC) and UK Medicines and Healthcare products … Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of “late infantile” and “early juvenile” MLD patients. It is currently
DEFA14C
jm9dj8omf2az lo
5 Oct 23
Additional information
4:48pm
DEFA14C
kdbdybm8tv2zrd
5 Oct 23
Additional information
4:45pm
DEFA14C
rocxrfw5132s9jp6kau
5 Oct 23
Additional information
4:40pm
DEFA14A
x5mhf3s
5 Oct 23
Additional proxy soliciting materials
9:07am
8-K
EX-99.1
m41y9y
5 Oct 23
Kyowa Kirin to Acquire Orchard Therapeutics
9:05am
8-K
EX-2.1
3tyup4nf
5 Oct 23
Kyowa Kirin to Acquire Orchard Therapeutics
9:05am
8-K
EX-99.1
sj31t8rg50sb
18 Sep 23
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
7:07am
424B3
dwd9 nkw2i
21 Aug 23
Prospectus supplement
4:32pm
8-K
EX-99.1
p0zswia9wplv93dyta
3 Aug 23
Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA
7:05am
8-K
EX-99.1
3hhlfr
26 Jun 23
Resulting in $34 Million of Additional Capital
7:06am
8-K
EX-99.1
fvm7wa5q3m77jjdgl4c9
15 May 23
OTL-200 Biologics License Application (BLA) submission completion anticipated in mid-2023
7:05am